Hirano T, Otake H, Kazama K, Wakabayashi K, Zama A, Shibasaki T, Tamura M, Endo K
Department of Nuclear Medicine, Gunma University, School of Medicine, Maebashi, Japan.
J Nucl Med. 1997 Nov;38(11):1741-9.
This study was performed to compare imaging ability between pentavalent 99mTc-DMSA and 201TlCl in primary and metastatic brain tumors and to evaluate the relationship between retention and histologic malignancy.
Patients with a brain tumor were selected by MRI and/or CT. Dynamic, early and delayed static SPECT images of the brain were obtained immediately, 30 min and 3 hr after intravenous administration of approximately 555 MBq 99mTc(V)-DMSA and 111 MBq 201Tl-Cl, respectively. Both studies were performed on separate days within a week. Uptake ratios, retention ratio and retention index were calculated and compared with tumor histology and malignancy grade.
One-hundred six studies were performed on 100 patients and 118 lesions were demonstrated: 16 glioblastomas, 13 anaplastic astrocytomas (Grade III), 19 astrocytomas (Grade II), 29 meningiomas, 11 schwannomas and 14 metastases. Approximately 93% and 88%, respectively, of primary and metastatic brain tumors were demonstrated by 99mTc(V)-DMSA and 201TlCl. The early uptake ratios were closely related to the tumor vascularity, but had no statistically significant difference in the tumor histology or histologic malignancy on either radiopharmaceuticals. The delayed uptake ratio, retention ratio and retention index were higher in malignant tumors than benign ones on 99mTc(V)-DMSA, however, there was no statistically significant difference between benign and malignant tumors on 201TlCl.
Technetium-99m(V)-DMSA washout from the tumor was highly dependent upon its histology and histologic malignancy. The delayed uptake ratio, retention ratio and retention index significantly reflected tumor histology and clearly distinguished between benign and malignant tumors with a statistically significant difference. There was no statistically significant difference in 201TlCl uptake or washout among the brain tumors. Technetium-99m-DMSA is superior to 201TlCl in imaging quality, sensitivity to brain tumors and specificity for differentiating benign tumors from malignant ones. These results could suggest the clinical utility of 99mTc(V)-DMSA in imaging primary and metastatic brain tumors and differentiating their histological malignancy grade noninvasively.
本研究旨在比较五价99mTc-DMSA和201TlCl在原发性和转移性脑肿瘤中的成像能力,并评估滞留与组织学恶性程度之间的关系。
通过MRI和/或CT选择脑肿瘤患者。分别在静脉注射约555MBq 99mTc(V)-DMSA和111MBq 201Tl-Cl后立即、30分钟和3小时获得脑部的动态、早期和延迟静态SPECT图像。两项研究均在一周内的不同日期进行。计算摄取率、滞留率和滞留指数,并与肿瘤组织学和恶性程度分级进行比较。
对100例患者进行了106项研究,共显示118个病灶:16例胶质母细胞瘤、13例间变性星形细胞瘤(III级)、19例星形细胞瘤(II级)、29例脑膜瘤、11例神经鞘瘤和14例转移瘤。99mTc(V)-DMSA和201TlCl分别显示了约93%和88%的原发性和转移性脑肿瘤。早期摄取率与肿瘤血管密切相关,但在两种放射性药物的肿瘤组织学或组织学恶性程度方面无统计学显著差异。在99mTc(V)-DMSA上,恶性肿瘤的延迟摄取率、滞留率和滞留指数高于良性肿瘤,然而,在201TlCl上良性和恶性肿瘤之间无统计学显著差异。
99mTc(V)-DMSA从肿瘤中的洗脱高度依赖于其组织学和组织学恶性程度。延迟摄取率、滞留率和滞留指数显著反映肿瘤组织学,能明显区分良性和恶性肿瘤,差异有统计学意义。脑肿瘤之间201TlCl的摄取或洗脱无统计学显著差异。99mTc-DMSA在成像质量、对脑肿瘤的敏感性以及区分良性肿瘤与恶性肿瘤的特异性方面优于201TlCl。这些结果提示99mTc(V)-DMSA在原发性和转移性脑肿瘤成像及无创区分其组织学恶性程度分级方面的临床应用价值。